KR20240139072A - 신경 변성 질환의 치료제 - Google Patents

신경 변성 질환의 치료제 Download PDF

Info

Publication number
KR20240139072A
KR20240139072A KR1020247028285A KR20247028285A KR20240139072A KR 20240139072 A KR20240139072 A KR 20240139072A KR 1020247028285 A KR1020247028285 A KR 1020247028285A KR 20247028285 A KR20247028285 A KR 20247028285A KR 20240139072 A KR20240139072 A KR 20240139072A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
sequence described
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028285A
Other languages
English (en)
Korean (ko)
Inventor
히로시 에구치
다카미 도미야마
도모히로 우메다
Original Assignee
데이진 화-마 가부시키가이샤
코우리츠 다이가꾸 호우진 오사카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이진 화-마 가부시키가이샤, 코우리츠 다이가꾸 호우진 오사카 filed Critical 데이진 화-마 가부시키가이샤
Publication of KR20240139072A publication Critical patent/KR20240139072A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
KR1020247028285A 2022-02-28 2023-02-27 신경 변성 질환의 치료제 Pending KR20240139072A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2022029825 2022-02-28
JPJP-P-2022-029825 2022-02-28
JP2022075095 2022-04-28
JPJP-P-2022-075095 2022-04-28
PCT/JP2023/007143 WO2023163187A1 (ja) 2022-02-28 2023-02-27 神経変性疾患の治療剤

Publications (1)

Publication Number Publication Date
KR20240139072A true KR20240139072A (ko) 2024-09-20

Family

ID=87766263

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028285A Pending KR20240139072A (ko) 2022-02-28 2023-02-27 신경 변성 질환의 치료제

Country Status (12)

Country Link
US (1) US20250171557A1 (https=)
EP (1) EP4488292A1 (https=)
JP (1) JPWO2023163187A1 (https=)
KR (1) KR20240139072A (https=)
AR (1) AR128627A1 (https=)
AU (1) AU2023226313A1 (https=)
CA (1) CA3244753A1 (https=)
CO (1) CO2024010819A2 (https=)
IL (1) IL314246A (https=)
MX (1) MX2024010163A (https=)
TW (1) TW202400643A (https=)
WO (1) WO2023163187A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
KR20260047599A (ko) * 2023-08-30 2026-04-08 데이진 화-마 가부시키가이샤 신경 변성 질환의 치료제
WO2025166040A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6334496U (https=) 1986-08-21 1988-03-05
WO2007053718A1 (en) 2005-10-31 2007-05-10 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
WO2021020047A1 (ja) 2019-07-29 2021-02-04 国立大学法人新潟大学 免疫誘導剤及び老化関連疾患の予防又は治療用医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812002B2 (en) * 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
KR102106821B1 (ko) * 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6334496U (https=) 1986-08-21 1988-03-05
WO2007053718A1 (en) 2005-10-31 2007-05-10 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
WO2021020047A1 (ja) 2019-07-29 2021-02-04 国立大学法人新潟大学 免疫誘導剤及び老化関連疾患の予防又は治療用医薬組成物

Non-Patent Citations (65)

* Cited by examiner, † Cited by third party
Title
Aichholzer et al., Alzheimers Res. Ther., (2021), 13 : 94
Anderson et al., Nat. Genet., (2002), 30 : 81-85
Anderson et al., Pigment Cell Melanoma Res. (2013), 26[4] : 470-486
Avgerinos et al., Ageing Res. Rev., (2021), 68 : 101339
Boi et al., Int. J. Mol. Sci., (2020), 21[22] : 8535
Bycroft et al., EMBO J., (1999), 18[2] : 297-305
Cai et al., Bioengineered, (2021), 12[2] : 11390-11398
Chung et al., J. Immunol., (2019), 183[5] : 5190-5198
Dani et al., Brain, (2018), 141[9] : 2740-2754
EMBL-EBI, "AlphaFold Protein Structure Database", "Transmembrane glycoprotein NMB", [online], (2021), [Seached in 2022], Internet <https : //alphafold.ebi.ac.uk/entry/Q99P91>
FBRI LLC, "ALZFORUM : NETWORKING FOR A CURE", "RESEARCH MODELS", [online], (1996), [Seached in 2022], Internet <https : //www.alzforum.org/research-models/alzheimers-disease>
Frigerio et al., Cell Rep., (2019), .27[4] : 1293-1306
Gerrits et al., Acta Neuropathol., (2021), 141 : 681-696
Gong et al., Nat. Metab., (2019), 1[5] : 570-583
Gouilly et al., Eur. J. Neurosci., (2022), doi : 10.1111/ejn.15613
Griciuc et al., Curr. Opin. Neurol., (2021), 34[2] : 228-236
Hafez et al., Neuroscience, (2012), 223 : 465-472
Hajj et al., J. Neuroinfla㎜ation, (2019), 16 : 87
Hee et al., Scientific Reports, (2017), 7 : 44064
Hsiao et al., Science, (1996), 274[5284] : 99-102
Huettenrauch et al., Acta Neuropathol. Commun., (2018), 6 : 108
Ishijima et al., Science Progress, (2021), 104[4] : 1-21
Jansen et al., Nat. Genet., (2019), 51[3] : 404-413
Jeremic et al., Ageing Res. Rev., (2021), 72 : 101496
Ji et al., Drugs, (2021), 81[10] : 1135-1152
Kawahara et al., Glia, (2016), 64[11] : 1938-1961
Keren-Shaul et al., Cell, (2017), 169 : 1276-1290
Krasemann et al., Immunity, (2017), 47 : 566-581
Kushwaha et al., Ann. Neurosci., (2018), 25 : 223-233
Li et al., FASEB J., (2010), 24[12] : 4767-4781
Malpetti et al., Brain, (2020), 143 : 1588-1602
Mao et al., Int. J. Mol. Sci., (2021), 22 : 9465
Maric et al., OncoTargets Ther., (2013), 6 : 839-852
Murata et al., J. Neurochem., (2015), 132 : 583-594
Nakano et al., Neuroscience, (2014), 277 : 123-131
Oakley et al., J. Neurosci., (2006), 26[40] : 10129-10140
Paasila et al., Brain Pathology, (2019), 29 : 726-740
Pardridge et al., Pharmaceuticals (2022), 15[3], Internet <https : //doi.org/10.3390/ph15010003>
Quek et al., J. Neuroinfla㎜ation, (2022), 19 : 58
Ripoll et al., J. Immunol., (2007), 178 : 6557-6566
Robinet et al., Scientific Reports, (2021), 11 : 10249
Rose et al., PLoS One, (2010), 5[8] : e12093
Satoh et al., Intractable Rare Dis. Res., (2019), 8[2] : 120-128
Shahidehpour et al., Neurobiol. Aging., (2021), 99 : 19-27
Shi et al., Front. Pharmacol., (2021), 12 : 794458
Shikano et al., J. Biol. Chem., (2001), 276[11] : 8125-8134
Stratoulias et al., EMBO J., (2019), 38 : e101997
Streit et al., Acta Neuropathol., (2009), 118[4] : 475-85
Suda et al., Nat. Aging, (2021), 1 : 1117-1126
Swanson et al., Acta Neuropathol. Commun., (2020), 8 : 170
Tolar et al., Int. J. Mol. Sci. (2021), 22[12] : 6355
Tse et al., Clin. Cancer Res., (2006), 12[4] : 1373-1382
Umeda et al., Acta Neuropathol., (2014), 127 : 685-698
Umeda et al., Front. Neurosci., (2021), 15 : 763476
Umeda et al., J. Neurosci. Res., (2011), 89 : 1031-1042
Wang et al., Cancer Sci.. (2021), 112 : 4187-4197
Wang et al., Cell, (2015), 160[6] : 1061-1071
Wang et al., J. Exp. Med., (2020), .217[9] : e20200785
Woollacott et al., J. Neuroinfla㎜ation, (2020), 17 : 234
Xie et al., Cancer Sci., (2019), 110[7] : 2237-2246
Yang et al., Am. J. Hum. Genet., (2018), 102[2] : 219-232
Zhang et al., Monoclon. Antibodies Immunodiagn. Immunother., (2013), .32[4] : 265-269
Zhu et al., Neurosci. Lett., (2022), 767 : 136300
Zhu et al., Neuroscience Letters, (2022), 767 : 136300
카와하라, 월간 「세포」, (2022), 54[2] : 110-114

Also Published As

Publication number Publication date
EP4488292A9 (en) 2025-06-18
CA3244753A1 (en) 2025-06-13
CO2024010819A2 (es) 2024-08-20
EP4488292A1 (en) 2025-01-08
AU2023226313A1 (en) 2024-08-01
TW202400643A (zh) 2024-01-01
US20250171557A1 (en) 2025-05-29
MX2024010163A (es) 2024-08-27
WO2023163187A1 (ja) 2023-08-31
IL314246A (en) 2024-09-01
AR128627A1 (es) 2024-05-29
JPWO2023163187A1 (https=) 2023-08-31

Similar Documents

Publication Publication Date Title
US20220340646A1 (en) Therapeutic agent or prophylactic agent for dementia
KR20240139072A (ko) 신경 변성 질환의 치료제
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
US20230141177A1 (en) Antibodies to misfolded amyloid beta
JP2023086132A (ja) アミロイドベータに対する抗体
WO2025047850A1 (ja) 神経変性疾患の治療剤
CN118804929A (zh) 神经变性疾病的治疗剂
HK40120105A (en) Therapeutic agent for neurodegenerative disorder
HK40113703A (zh) 神经变性疾病的治疗剂
AU2024332046A1 (en) PHARMACEUTICAL AND ANTI-gpNMB ANTIBODY FOR REMOVING DISEASE-ASSOCIATED CELLS
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia
HK40031828B (en) Therapeutic agent or prophylactic agent for dementia
HK40017344B (en) Antibodies to amyloid beta
HK40017344A (en) Antibodies to amyloid beta
HK1210031B (zh) 痴呆症治疗药或预防药

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240822

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application